Published in Control Clin Trials on August 01, 2003
Aiming to increase birth weight: a randomised trial of pre-pregnancy information, advice and counselling in inner-urban Melbourne. BMC Public Health (2006) 0.89
The change in motivating factors influencing commencement, adherence and retention to a supervised resistance training programme in previously sedentary post-menopausal women: a prospective cohort study. BMC Public Health (2015) 0.77
Factors associated with compliance and non-compliance by physicians in a large-scale randomized clinical trial. Trials (2006) 0.75
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. JAMA (2006) 5.75
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA (2006) 3.29
Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control (2002) 3.27
Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol (2010) 3.17
Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol (2008) 3.05
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 2.97
Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst (2011) 2.84
Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women's Health Initiative. J Womens Health (Larchmt) (2013) 2.81
Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol (2008) 2.79
The Women's Health Initiative Dietary Modification trial: overview and baseline characteristics of participants. Ann Epidemiol (2003) 2.64
Frequency and predictive value of a mammographic recommendation for short-interval follow-up. J Natl Cancer Inst (2003) 2.64
Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res (2003) 2.49
Low-fat dietary pattern and change in body-composition traits in the Women's Health Initiative Dietary Modification Trial. Am J Clin Nutr (2010) 2.43
Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst (2007) 2.37
Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab (2004) 2.35
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol (2014) 2.25
Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial. Arch Intern Med (2005) 2.17
Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst (2005) 2.16
Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer (2007) 2.01
Biomarker-calibrated energy and protein consumption and increased cancer risk among postmenopausal women. Am J Epidemiol (2009) 1.98
Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study. Ann Intern Med (2014) 1.87
An analysis of dialysis training in the United States and Canada. Am J Kidney Dis (2002) 1.78
Influence of stressors on breast cancer incidence in the Women's Health Initiative. Health Psychol (2009) 1.75
Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst (2008) 1.72
Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst (2006) 1.70
Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.67
American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol (2003) 1.64
Sex hormone levels and risk of breast cancer with estrogen plus progestin. J Natl Cancer Inst (2013) 1.60
Genetic variants in the MRPS30 region and postmenopausal breast cancer risk. Genome Med (2011) 1.55
Alcohol consumption and risk of postmenopausal breast cancer by subtype: the women's health initiative observational study. J Natl Cancer Inst (2010) 1.55
Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med (2003) 1.51
Body mass index and waist circumference in relation to lung cancer risk in the Women's Health Initiative. Am J Epidemiol (2008) 1.48
Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.46
Low-fat high-fiber diet decreased serum and urine androgens in men. J Clin Endocrinol Metab (2005) 1.42
Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev (2008) 1.42
Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology (2004) 1.38
Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.37
Effects of prenatal methamphetamine exposure on fetal growth and drug withdrawal symptoms in infants born at term. J Dev Behav Pediatr (2003) 1.36
Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial. J Clin Oncol (2009) 1.35
Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res (2012) 1.35
Development of a glycemic index database for food frequency questionnaires used in epidemiologic studies. J Nutr (2006) 1.35
Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer (2009) 1.34
Comorbidities and mammography use interact to explain racial/ethnic disparities in breast cancer stage at diagnosis. Cancer (2011) 1.33
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol (2002) 1.32
Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas (2006) 1.31
Improvement of nutritional status after initiation of maintenance hemodialysis. Am J Kidney Dis (2002) 1.30
Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study. Cancer Epidemiol Biomarkers Prev (2009) 1.29
American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol (2008) 1.29
Design, feasibility, and acceptability of an intervention using personal digital assistant-based self-monitoring in managing type 2 diabetes. Contemp Clin Trials (2007) 1.27
Recreational physical activity, body mass index, and survival in women with colorectal cancer. Cancer Causes Control (2012) 1.26
Nutrition and physical activity cancer prevention guidelines, cancer risk, and mortality in the women's health initiative. Cancer Prev Res (Phila) (2014) 1.26
A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.22
The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab (2002) 1.20
The effect of calcium plus vitamin D on risk for invasive cancer: results of the Women's Health Initiative (WHI) calcium plus vitamin D randomized clinical trial. Nutr Cancer (2011) 1.20
Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat (2012) 1.20
A simple self-report diary for assessing psychosexual function in hypogonadal men. J Androl (2003) 1.19
Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease. Kidney Int (2003) 1.18
Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Natl Cancer Inst (2011) 1.17
Fatty acid consumption and risk of fracture in the Women's Health Initiative. Am J Clin Nutr (2010) 1.16
Diet drink consumption and the risk of cardiovascular events: a report from the Women's Health Initiative. J Gen Intern Med (2014) 1.15
Management of bloody nipple discharge. Curr Treat Options Oncol (2002) 1.12
Migraine history and breast cancer risk among postmenopausal women. J Clin Oncol (2010) 1.11
Variation in the FGFR2 gene and the effect of a low-fat dietary pattern on invasive breast cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.07
Aromatase inhibitor-associated arthralgias. J Clin Oncol (2009) 1.06
Dietary fish intake and incident atrial fibrillation (from the Women's Health Initiative). Am J Cardiol (2010) 1.05
Conduct of the Women's Health Initiative randomised trial evaluating estrogen plus progestin: implications for breast cancer findings. J Fam Plann Reprod Health Care (2013) 1.05
Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. Cancer Epidemiol (2013) 1.03
The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment. J Natl Cancer Inst (2011) 1.03
Interaction between body mass index and central adiposity and risk of incident cognitive impairment and dementia: results from the Women's Health Initiative Memory Study. J Am Geriatr Soc (2011) 1.03
Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. Int J Cancer (2006) 1.03
Adherence to oral endocrine therapy for breast cancer: a nursing perspective. Clin J Oncol Nurs (2008) 1.02
Association between sleep and breast cancer incidence among postmenopausal women in the Women's Health Initiative. Sleep (2013) 1.01
Hormonal factors and risks of esophageal squamous cell carcinoma and adenocarcinoma in postmenopausal women. Cancer Prev Res (Phila) (2011) 1.00
Promoting healthy choices in non-chain restaurants: effects of a simple cue to customers. Health Promot Pract (2012) 1.00
Estrogen plus progestin and colorectal cancer incidence and mortality. J Clin Oncol (2012) 1.00
Long-term effects of conjugated equine estrogen therapies on domain-specific cognitive function: results from the Women's Health Initiative study of cognitive aging extension. J Am Geriatr Soc (2010) 1.00
Benchmarks for designing two-stage studies using modified mini-mental state examinations: experience from the Women's Health Initiative Memory Study. Clin Trials (2006) 0.99
The ADH3*2 and CYP2E1 c2 alleles increase the risk of alcoholism in Mexican American men. Exp Mol Pathol (2003) 0.99
Changes in food sources of dietary fat in response to an intensive low-fat dietary intervention: early results from the Women's Health Initiative. J Am Diet Assoc (2003) 0.96
Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. Breast Cancer Res (2014) 0.95
A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease. Breast Cancer Res Treat (2008) 0.95
Resolving the onset of antidepressants' clinical actions: critical for clinical practice and new drug development. J Clin Psychopharmacol (2006) 0.93
Exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 0.93
Quantifying mediating effects of endogenous estrogen and insulin in the relation between obesity, alcohol consumption, and breast cancer. Cancer Epidemiol Biomarkers Prev (2012) 0.92
Biological significance of interventions that change breast density. J Natl Cancer Inst (2003) 0.92